Lucid Diagnostics Files Q1 2025 10-Q

Ticker: LUCD · Form: 10-Q · Filed: May 13, 2025 · CIK: 1799011

Sentiment: neutral

Topics: 10-Q, financials, quarterly-report

Related Tickers: LUCD

TL;DR

Lucid Diagnostics Q1 2025 10-Q filed. Financials updated.

AI Summary

Lucid Diagnostics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including changes in common stock, preferred stock, additional paid-in capital, and retained earnings. The company's principal executive offices are located at 360 Madison Avenue, New York, NY.

Why It Matters

This filing provides investors with the latest financial snapshot of Lucid Diagnostics, crucial for understanding the company's performance and financial health in early 2025.

Risk Assessment

Risk Level: low — This filing is a routine quarterly report and does not contain significant new risk disclosures.

Key Numbers

Key Players & Entities

FAQ

What are the key changes in Lucid Diagnostics' equity accounts for Q1 2025 compared to the previous period?

The filing details changes in us-gaap:CommonStockMember, us-gaap:SeriesBPreferredStockMember, LUCD:SeriesBOnePreferredStockMember, us-gaap:AdditionalPaidInCapitalMember, and us-gaap:RetainedEarningsMember for the period ending March 31, 2025, compared to December 31, 2024, and prior periods.

When was this 10-Q filing submitted to the SEC?

The filing was submitted on May 13, 2025.

What is Lucid Diagnostics' primary business classification?

Lucid Diagnostics Inc. is classified under SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841].

Where is Lucid Diagnostics Inc. headquartered?

The company's principal executive offices are located at 360 Madison Avenue, 25th Floor, New York, NY 10017.

What is the SEC file number for Lucid Diagnostics?

The SEC file number for Lucid Diagnostics Inc. is 001-40901.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Lucid Diagnostics Inc. (LUCD).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing